Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

• Status: Recruiting
• Trial end date: 2028-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stanford University
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Ketamine; Naltrexone

Criteria

Eligibility Criteria for Participants with OCD:

Inclusion Criteria:

• Ages 18-65

• Meet the criteria for OCD diagnosis

• Failed at least 1 prior trial of standard first-line OCD treatment

• Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.

• Able to provide informed consent

Exclusion Criteria:

• prior naltrexone or ketamine use/exposure

• Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician

• Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control

• the presence of metal in the body that is contraindicated for MRI scans

Eligibility Criteria for Healthy Volunteers:

Inclusion Criteria:

• Ages 18-65

• Able to provide informed consent

Exclusion Criteria:

• current or past use of psychotropic medication

• pregnant or nursing females

• the presence of metal in the body that is contraindicated for MRI scans